DaVita (NYSE:DVA) Downgraded by StockNews.com to Hold

DaVita (NYSE:DVA - Get Free Report) was downgraded by stock analysts at StockNews.com from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Friday.

DVA has been the topic of several other research reports. Cowen reiterated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Barclays upped their price target on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a research report on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $166.33.

DaVita Stock Up 0.1 %

Shares of NYSE:DVA traded up $0.19 during midday trading on Friday, hitting $150.60. 662,227 shares of the company's stock were exchanged, compared to its average volume of 784,907. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The company has a market cap of $12.05 billion, a PE ratio of 14.02, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. The stock has a 50 day moving average price of $158.18 and a 200-day moving average price of $157.57. DaVita has a 12 month low of $125.64 and a 12 month high of $179.60.

Remove Ads

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, sell-side analysts anticipate that DaVita will post 10.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. lifted its holdings in DaVita by 20.9% during the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock worth $237,716,000 after buying an additional 275,284 shares during the last quarter. Northern Trust Corp lifted its stake in DaVita by 12.5% in the 4th quarter. Northern Trust Corp now owns 740,774 shares of the company's stock valued at $110,783,000 after buying an additional 82,326 shares in the last quarter. JPMorgan Chase & Co. grew its stake in DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after acquiring an additional 92,014 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in DaVita by 14.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 466,046 shares of the company's stock worth $69,697,000 after purchasing an additional 57,386 shares during the period. Finally, Amundi lifted its position in DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after buying an additional 240,126 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.